Interleukin-7 Optimizes FOXP3+CD4+ Regulatory T Cells Reactivity to Interleukin-2 by Modulating CD25 Expression

Federico Simonetta1,2,3, Nicolas Gestermann1,2, Stéphane Bloquet4, Christine Bourgeois1,2*

1. INSERM, U1012, Le Kremlin-Bicêtre, France, 2. Univ Paris-SUD, UMR-S1012, Le Kremlin-Bicêtre, France, 3. Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, Geneva, Switzerland, 4. Animalerie centrale, Faculté de Médecine Paris-Sud, Univ Paris-Sud, Le Kremlin-Bicêtre, France

*christine.bourgeois@u-psud.fr

Abstract

The vast majority of Foxp3 regulatory T cells (Treg) exhibits constitutive expression of CD25 (IL-2Rα), which allows the constitution of the high affinity IL-2Rαβγ receptor, ensuring efficient IL-2 binding by Treg. Maintenance of CD25 expression at Treg surface depends on both cell intrinsic factors and environmental stimuli such as IL-2 itself. Whether other factors can participate to maintenance of CD25 expression in vivo is at present unknown. In the present work we demonstrated that IL-7, a gamma-chain cytokine exerting a crucial role in T cell development and homeostasis, is able and necessary to sustain the expression of high levels of CD25 at Treg surface. We demonstrated that, during in vitro cultures performed in the absence of IL-2, IL-7 is able to sustain CD25 expression at Treg surface through a transcriptional mechanism. By studying mice in which IL-7 signaling is either genetically impaired or increased and by employing adoptive transfer murine models, we demonstrated that IL-7 is necessary for sustained expression of CD25 at Treg surface in vivo. To ascertain the biological impact of IL-7 mediated modulation of CD25 expression, we demonstrated that IL-7 modulation of CD25 expression at Treg surface affected their ability to efficiently bind IL-2 and transduce IL-2 signaling. Finally, we demonstrated that IL-7 dependent modulation of CD25 associated with potentiated IL-2 induced expansion of Treg in vivo. Collectively, our results identify IL-7 as a necessary factor contributing to sustained CD25 expression at Treg surface in vivo thereby affecting their ability to efficiently react to IL-2.
Introduction

CD4+FOXP3+ T cells represent a subset of CD4+ T cells crucial for immune-responses regulation and prevention of immune-pathology [1]. CD4 Treg were initially characterized by their constitutive expression of CD25 [1]–[2], the alpha chain of interleukin-2 (IL-2) receptor. Together with the beta chain CD122 and the common gamma chain CD132, CD25 expression allows the constitution of the high affinity IL-2 receptor (IL-2Rαβγ). In accordance to their constitutive CD25 expression, Treg cells are sensitive to IL-2 signaling on which they are dependent for their development [3]–[6], their peripheral homeostasis [7]–[11], and their function [12]–[13]. Importantly, Treg cells do not produce IL-2 [14] and are dependent on consumption of IL-2 produced by effector conventional CD4 T cells [11], [15]. Given the very limited amounts of IL-2 available in vivo at the steady state and during the first phases of immune responses, expression of the high affinity IL-2Rαβγ is essential for rapid cytokine binding and signal transduction by Treg, the absence of CD25 resulting in their impaired competitive fitness [3].

Mechanisms regulating CD25 expression at Treg surface are only incompletely understood. FOXP3, a transcription factor essential for Treg development and function [16]–[18] sustains CD25 expression at Treg surface by binding the Cd25 promoter both directly [19]–[21] and through its interaction with other transcription factors such as NFAT [22] and AML1/Runx1 [23]. In addition to cell intrinsic mechanisms, environmental factors modulate CD25 transcription and expression in Treg. IL-2 is the best established soluble factor inducing CD25 transcription on conventional T cells [24]. Regarding Foxp3+ Treg, IL-2 induces this positive feedback regulation on its own receptor through a Stat5 dependent mechanism: inhibition of STAT5 renders Treg unable to up-regulate CD25 upon IL-2 stimulation and displaying impaired function in vivo [25]. Reduction in IL-2 availability as a result of genetically disrupted IL-2 production leads to down-regulation of CD25 at Treg surface expression [26]. Similarly, increased proportions of CD25 low Treg in ageing has been associated with low IL-2 availability in aged animals [27]. In vitro data suggest that other cytokines of the common gamma-chain family, such as IL-4 and IL-7, could modulate CD25 expression at Treg surface [28] but the in vivo relevance of these factors is unknown.

IL-7 plays a major role in T cell development and homeostasis. Treg have been longly been considered to be barely sensitive to IL-7 [29]–[30] in accordance to low levels of expression of CD127, the alpha chain of IL-7 receptor, at their surface [31]–[33]. However, both murine and human Treg cells display significant expression of CD127 at levels sufficient to allow IL-7 signal transduction as revealed by STAT5 phosphorylation [34]–[36]. Moreover, we and others recently demonstrated that, similarly to its action on conventional T cells, IL-7 directly sustains Treg survival in vitro [28], [34] and plays an essential role in Treg homeostasis in vivo both in secondary lymphoid organs [37]–[38] and at site where Treg exhibit high levels of CD127 expression [39]. We hypothesized that, in
addition to its direct effect on survival, IL-7 could in part exert its role on Treg homeostasis in conjunction with IL-2. In the present work we showed in vitro that IL-7 is able to sustain CD25 expression at Treg surface in the absence of IL-2 by sustaining CD25 transcription. Moreover, we showed that IL-7 is necessary in vivo for sustained expression of CD25 at Treg surface. Finally we demonstrated that IL-7 modulation of CD25 expression influenced Treg ability to efficiently bind IL-2 and transduce IL-2 signaling, and drastically affected IL-2 induced Treg expansion in vivo.

**Material And Methods**

**Ethics Statement**

Mice were kept under specific pathogen free conditions in accordance with institutional guidelines in compliance with French and European animal welfare regulations (agreement B-94-043-12, delivered by the French veterinary authorities). All animal studies were approved by the ethics Committee of University Paris.

Sud and protocols conducted were authorized by French veterinary authorities (licence 94–440) in accordance with French and European guidelines.

**Mice**

6 to 8 weeks old C57Bl/6 were purchased from Janvier Labs. Mice deficient for Rag gene (Rag-/-) or for Rag and IL-7 genes (Rag-/-IL-7-/-) were used as hosts for adoptive transfer experiments. Rag-/- IL-7-/- mice were kindly provided by Dr. Benedict Seddon. IL-7Rα-/- mice were purchased from the Jackson Laboratory. IL-7-/- and IL-7 transgenic (IL-7 Tg) mice were kindly provided by Dr. Sophie Ezine. Foxp3/GFP mice were purchased from the Jackson Laboratory. All mice were kept under specific pathogen free conditions and all experiments were performed according to institutional guidelines of the European Community.

**Cell purification**

Single cell suspensions were prepared from lymph nodes (pooled inguinal, brachial, axillary and mesenteric) and spleens HBSS containing 2% FCS (PAA Laboratories GmbH). For total CD4 T cells transfer, CD4 T cells were isolated using BD magnetic beads (Becton-Dickinson). For CD4+CD25+ Treg adoptive transfer experiments, CD4+ CD25+ cells were isolated by magnetic beads accordingly to manufacturer instructions (Miltenyi). Cell purity for FOXP3 was >90%. For in vitro experiments, CD4+ FOXP3/GFP+ cells were FACS sorted from Foxp3/GFP mice (Jackson Laboratory) on a FACSARia cell sorter (BD Biosciences). Cell purity for FOXP3 was >99%.
FACS analysis

Extracellular staining was preceded by incubation with purified anti-CD16/32 antibodies (FcγRIII/II block, 2.4G2) (eBioscience) to block nonspecific staining. Cells were stained with FITC-, PE-, PECy5-, PECy7-APC- APCAlexa750- or APC-H7-labeled or biotinylated appropriate antibodies including: CD4 (GK1.5); TCRβ (H57-597); CD25 (PC61.5), CD122 (5H4) or appropriate isotype Abs. Streptavidin-FITC, PECy5 or PECy7 were used to develop biotinylated Abs. All Abs were purchased from eBioscience except APC-H7-labeled antibodies (BD Bioscience). Intranuclear FOXP3 staining was performed using eBioscience PE- or APC conjugated FOXP3 staining buffer set (FJK-16s). Six-color flow cytometry was performed with a FACSCanto cytometer (BD Biosciences) and data files were analyzed using FlowJo software (Tree star Inc).

Real time PCR

Total RNA was extracted with a RNasea Mini kit (Qiagen) and RNA was converted to cDNA using an Enhanced Avian HS reverse transcriptase–PCR (Sigma-Aldrich). Subsequent real-time PCR was performed using the SsoFast Probes Supermix (Bio-Rad). Primers for detection of murine CD25 (Mm00434261_m1) and Hprt1 (Mm00446968_m1) were purchased as Assays-on-Demand from Applied Biosystems. Samples were run in triplicate on a CFX96 Real-Time PCR Detection System (Bio-Rad).

CFSE labelling

When required, cell division of transferred T cells was assessed by CFSE labelling (Sigma) using standard methods. Cells were resuspended in PBS in a concentration of 10^7/ml and incubated with CFSE at final concentration of 5 μM for 10 min at 37°C, followed by two washes in ice cold HBSS containing 10% FCS.

Cytokines

Recombinant murine IL-2 (rmIL-2) and IL-7 (rmIL-7) were purchased from Immunotools.

IL-2 binding assay

A Fluorokine assay kit (R&D Systems) was used to evaluate the binding of IL-2 by Tregs cells following manufacturer’s instructions. Briefly, cells were incubated with biotinylated IL-2 in 25 μl of serum-free PBS for 30 min on ice. Biotinylated IL-2 was revealed with a PECy7 streptavidin. Binding values were determined by the median fluorescence intensities (MFIs) of the IL-2-biotin-streptavidin complex on CD4+FOXP3+ cells. Measurement of binding of an unrelated biotinylated protein was used as a negative control.
STAT5 phosphorylation experiments

Splenic cells were incubated for 10 min at 37°C with increasing doses of IL-2 (0, 0.1, 1, 10 ng/ml) (Immuno Tools) and immediately fixed in 2% paraformaldehyde. Cells were made permeable by incubation in 90% methanol and then were stained with CD4, TCRβ, FOXP3 antibody and primary rabbit antibody to phosphorylated STAT5 or isotype control (Cell Signaling) revealed with an anti-rabbit Alexa-647 conjugated secondary antibody. Stat5 phosphorylation was then determined by flow cytometry in CD4+TCRβ+FOXP3+ cells.

Adoptive transfer experiments

Purified CD4+ CD25+ cells (1 × 10^6) were injected into Rag-deficient mice (Rag-/-) or Rag-/- mice that were also deficient for IL-7 (Rag-/- IL-7-/-). Mice were then left untreated or treated with IL-2/anti-IL-2 complexes generated as previously described [40]. Briefly, 1 μg of rmIL-2 was co-incubated with 5 μg of anti-IL-2 mAb (clone JES6-1 purchased from R&D) for 30 min at +37°C. Mice were i.p. injected with IL-2/anti-IL-2 complexes (1 μg plus 5 μg) once daily for three days. Six days after transfer, spleens were harvested and analyzed.

Statistical analyses

Statistical analyses were performed using unpaired Student T test with Graph Pad Software.

Results

IL-7 modulates CD25 expression on regulatory T cells in vitro

In order to assess the possibility that CD25 expression on Treg cells can be dynamically regulated by IL-7 availability, we FACS sorted CD4+ FOXP3/GFP+ lymph nodes and spleen cells from FOXP3/GFP mice and cultured them overnight with medium alone or in the presence of IL-7 or IL-2 as control.

As both IL-2 and IL-7 have been reported by our and other groups to inhibit Treg cell death [28], [34] and in order to study the effect of cytokines on CD25 expression independently from their effect on survival, we restricted our phenotypic analysis to live Treg cells gating as shown in Fig. 1A. As previously described, we found a significant increase in proportions of live Treg cells in cells cultured in the presence of either IL-7 or IL-2 compared to cells cultured in medium alone (data not shown). To further assess whether, in addition to affecting survival, culture in the presence of IL-7 and IL-2 could affect cellular metabolic fitness thus resulting in non-specific modulation of protein expression, we analyzed the expression at live Treg surface of CD4, a molecule whose transcription and surface turnover are affected by cellular stress. As shown in S1A Figure, CD4 was expressed at similarly high levels on Treg independently from culture conditions. Looking at CD25 expression, we
observed, as expected, a decreased CD25 expression on CD4+ FOXP3+ T cells incubated in the absence of cytokine (Fig. 1B, C) when compared to levels expressed ex vivo. As previously reported, the addition of IL-2 to overnight cultures sustained high levels of CD25 expression on Treg cells (Fig. 1B, C). Interestingly, the addition of IL-7 to cultures prevented the decrease in CD25 expression on Treg cells (Fig. 1B, C). We performed similar analysis at the mRNA level to determine whether IL-7 affected CD25 surface expression through a transcriptional mechanism. As expected, CD25 mRNA decreases upon in vitro 24 h incubation in the absence of cytokine while addition of IL-2 to culture medium maintained CD25 transcription (Fig. 1D). As demonstrated at the protein level, Treg cells incubated in the presence of IL-7 maintained CD25 transcription (Fig. 1D). To assess whether IL-7 effect on IL-2 receptor subunits was specific to CD25, we next assessed CD122 levels at Treg surface upon culture in the presence of IL-7 or IL-2. We failed to observe any significant difference in
CD122 levels between cells cultured in the presence or in the absence of IL-7 (S1A, B Figure). Conversely, in Treg cells cultured with IL-2, receptor occupancy by the cytokine prevented CD122 staining by specific antibodies leading to falsely undetectable levels of CD122 expression (S1A, B Figure). These in vitro results demonstrate that, in addition to its positive effects on Treg survival, IL-7 is able to sustain CD25 transcription and surface expression on Treg cells in the absence of IL-2 signaling.

IL-7 modulates CD25 expression on regulatory T cells in vivo

To confirm the effect of IL-7 on CD25 expression in vivo, we first examined CD25 expression on Treg from mice in which IL-7 signaling was disrupted (IL-7Rα-/- or IL-7-/-) or increased (IL-7Tg). We previously reported that IL-7 availability significantly affects Treg cell numbers in these mouse strains in accordance with a role for IL-7 on Treg peripheral homeostasis [34]. After Treg identification as FOXP3 expressing CD4 T cells, we observed lower percentages of CD25 expressing Treg on splenic FOXP3+ CD4+ cells from IL-7Rα-/- or IL-7-/- mice than on wild type cells (WT 72.8±3.4%, IL-7Rα-/- 38.3±6.6%, IL-7-/- 54.1±8.8%), (Fig. 2A and Fig. 2B, upper panel). Conversely, CD25 expression was modestly but significantly increased on splenic Treg cells isolated from IL-7Tg mice when compared to wild type mice (Fig. 2A and Fig. 2B, upper panel). Studies of median of CD25 expression on Treg from the different mouse strains showed equivalent profile: reduced CD25 Median Fluorescence Intensity (MFI) on Treg isolated from IL-7Rα-/- and IL-7-/- mice, whereas a significant increase was detected on Treg from IL-7 Tg mice (Fig. 2B, lower panel). These results indicate that IL-7 quantitatively affects CD25 expression on peripheral CD4+ FOXP3+ T cells in vivo.

As IL-7 is essential for thymic development of T cells, including Treg [30], we determined whether IL-7 induced similar effects on wild type Treg in vivo. CD4 T cells were isolated from B6 lymph nodes and spleen, CFSE stained and adoptively transferred into either C57Bl/6, RAG-/- or IL-7-deficient RAG-/-IL-7-/- host mice. Injected CD4 T cells were examined in host spleens 18 h after transfer. At this time point, no CFSE dilution was detected among injected CD4 T cells (data not shown), thus confirming the absence of proliferation as previously described [41]–[42]. Treg cells transferred into RAG-/- IL-7-/- but not RAG-/- IL-7 competent hosts significantly down-regulated CD25 surface expression when compared to Treg transferred into either WT (Fig. 2C–D). No CD25 up-regulation was detected on CD4+ FOXP3- cells in all studied hosts (data not shown). Collectively, these in vivo experiments support our in vitro results and further document that endogenous IL-7 is necessary for maintenance of CD25 expression on Treg cells in vivo.
IL-7 mediated modulation of CD25 expression affects IL-2 binding ability by Treg

CD25 is necessary for the constitution of IL-2 receptor with the highest affinity and plays a major role in Treg biology. We therefore assessed whether CD25 modulation by IL-7 effectively affected IL-2 binding capacity by Treg. We first studied *ex vivo* IL-2 binding capacity by both conventional FOXP3- and regulatory FOXP3+ CD4 T cells. FOXP3+ Treg efficiently bound IL-2 at their surface (Fig. 3A) accordingly to their constitutive CD25 surface expression. Conversely, FOXP3-conventional CD4 T cells failed to bind detectable levels of IL-2 (Fig. 3A) in agreement to their lack of CD25 surface expression at the steady state. We next assessed IL-2 binding capacity by Treg incubated overnight in the presence or absence of IL-7. As shown in Fig. 3B, prior IL-7 incubation provided enhanced binding capacity for IL-2: a two fold increase in IL-2 fluorokine was detected. To confirm *in vivo* the effect of IL-7 signaling on IL-2 binding capacity by Treg, similar experiments were performed *ex vivo* by analyzing binding of IL-2 fluorokine by splenic Treg isolated from WT, IL-7Rα-/-, IL-7-/- and IL-7 Tg mice. Accordingly to our *in vitro* results, Treg issued from IL-7Rα-/- and IL-7-/- exhibited significantly reduced IL-2 binding capacities compared to WT Treg and conversely Treg from IL-7 Tg mice exhibited significantly higher IL-2 binding capacity (Fig. 3C). Collectively these results demonstrated that IL-7 signaling modulates CD25 expression which affects IL-2 binding capacity by Treg.

IL-7 signaling optimizes IL-2 signal transduction by Treg

We next evaluated whether the decrease in CD25 expression and IL-2 binding capacity observed in Treg in the absence of IL-7 signaling led to a decreased IL-2 signaling transduction. To this aim we assessed STAT5 phosphorylation following short term (10 min) IL-2 incubation on CD4+FOXP3+ splenocytes from WT or IL-7Rα-/- mice. As shown in Fig. 4A, following exposure to IL-2, STAT5 was promptly phosphorylated in WT Treg in a dose dependent manner. Similarly to what observed for IL-2 binding, STAT5 phosphorylation upon IL-2 incubation was exclusively observed in FOXP3+ Treg, while no phosphorylation was detected in FOXP3- conventional CD4 T cells accordingly to their low CD25 expression (S2 Figure). Quantitative analysis of pSTAT5 revealed that IL-7Rα-/- Treg cells presented significantly lower pSTAT5 than WT Treg cells in context of low IL-2 availability (Fig. 4B), indicating that these Treg cells were less responsive to IL-2.
Importantly, WT or IL-7Rα-/- mice displayed similar levels of CD122, the β-chain of the IL-2 receptor which plays a major role in IL-2 signal transduction (data not shown). These findings indicate that IL-7 signaling optimizes Treg responsiveness to IL-2 by interfering with CD25 but not CD122 expression.

IL-7 affects IL-2 induced Treg expansion \textit{in vivo}

Although not strictly required for Treg proliferation during lymphopenia \cite{9}, IL-2 administration in this setting has been shown to strongly increase Treg expansion \cite{10}. Zhang et al. have suggested that IL-2 and lymphopenia could somehow synergize to induce Treg expansion. As lymphopenia is typically characterized by increased levels of IL-7 \cite{43} and having shown that IL-7 availability increases Treg reactivity to IL-2, we speculated that IL-7 could affect IL-2 induced Treg expansion. We transferred purified Treg cells into Rag deficient mice either competent or deficient for IL-7 that were additionally treated or not with IL-2/αIL-2 complexes at d1, 2 and 3. Treg cell recovery at day 1, established before the first IL-2 injection, allowed confirming that similar initial number of Treg were present in both IL-7 deficient and competent hosts prior to IL-2 complex injection (data not shown). At day 6, we determined CD4+ FOXP3+ Treg proliferation profiles and cell numbers. As we previously reported \cite{37}, CD4+ FOXP3+ Treg proliferation was detected both in IL-7 deficient host compared to IL-7 competent hosts (Fig. 5A) but Treg expansion was significantly increased in IL-7 competent hosts, accordingly to a role for IL-7 for Treg expansion in empty hosts in the absence of IL-2. Similarly, IL-2/αIL-2 complexes injection induced strong Treg proliferation in both IL-7 competent or IL-7 deficient Rag-/- mice (Fig. 5A) suggesting IL-7 availability did not affect significantly IL-2 dependent Treg proliferation. We next analyzed Treg recovery at day 6: IL-2 mediated effect on Treg expansion was essentially detected in IL-7 competent hosts whereas low Treg numbers were present in the absence of IL-2/αIL-2 complexes injection but also in IL-7 deficient hosts treated with IL-2/αIL-2 complexes. IL-2 induced Treg expansion was approximately four-fold reduced in IL-7 deficient compared to IL-7 competent mice (Fig. 5B). Collectively, these results indicate that, although not
Fig. 4. IL-7 signaling affected IL-2 signaling transduction by Treg. WT or IL-7R−/− splenocytes were treated with increasing doses of rmIL-2 for 10 min. Stat5 phosphorylation was then determined by flow cytometry in CD4+TCRβ+FOXP3+ cells. (A) Representative dot plots gated on TCRβ+ lymphocytes showing gating for CD4+FOXP3+ cells and FACS profiles of phospho-STAT5 at different IL-2 doses. Isotype controls are indicated. (B) Relative phospho-
being necessary for Treg proliferation in response to IL-2, IL-7 modulates IL-2 induced Treg expansion in lymphopenic hosts.

Discussion

IL-2 represents the principal factor regulating Treg function and homeostasis. Both at steady state and during immune responses, IL-2-producing conventional CD4 T cells represent the main source of IL-2 employed by Treg [11]. Numbers of Treg and IL-2 producing CD4 T cells are finely associated in a quorum sensing-like system [15]. However, IL-7 has been recently reported by our and other groups as a complementary factor affecting Treg homeostasis [37]–[39]. In the present report we unraveled an interplay between these two cytokines, demonstrating in vivo that IL-7 availability affects CD25 expression and IL-2 usage by murine Treg.

CD25 levels at Treg surface are dictated by both cell intrinsic factors, such as FOXP3 expression, and environmental stimuli, mainly IL-2 signaling. IL-2 exerts its positive feedback regulation on its own receptor through STAT5 mediated CD25 transcription in both conventional T cells [24] and Treg cells [25]. In addition, IL-2 signaling sustains, specifically in Treg, FOXP3 expression which in turn induces CD25 transcription [19]–[20]. We showed here that IL-7 is both sufficient and necessary to maintain CD25 expression at Treg surface in vivo. Such IL-7 dependent modulation of CD25 expression develops through a transcriptional mechanism. Molecular pathways involved in this process were not investigated in this report. However similarly to IL-2, IL-7 has been reported to induce STAT5 phosphorylation [34]–[36] and to influence FOXP3 expression [28] in Treg, thus acting on both major pathways involved in maintenance of CD25 expression at Treg surface. Importantly such potentiating role of IL-7 on CD25 expression has been previously described on activated conventional T cells [44]–[47]. However, it may provide an even more potentiating effect on Treg which are highly dependent on IL-2 signaling for their survival and function.

When considering Treg homeostasis, such strategy could be especially relevant in context of ageing, a context of T cell lymphopenia in which IL-2 levels available are reduced. During ageing, proportions of Treg cells are increased [26]–[27]. It is tempting to speculate that IL-7 signaling could optimize the consumption of residual IL-2 and thus preserve their homeostasis. Importantly, increased proportion of CD25- Treg has been described during ageing, presumably due to the low availability in IL-2. Raynor et al., have suggested that Treg become dependent on other cytokines, namely IL-15 to compensate for the IL-2 deprived environment [27]. Whether IL-7 signaling could concomitantly limit the down-regulation of CD25 at aged Treg surface is currently under investigation. In
Fig. 5. IL-7 signaling is required for IL-2 induced expansion of CD4+CD25+ Treg cells in lymphopenic hosts. CFSE-labeled, purified CD4+CD25+ T cells were transferred into Rag-/- and Rag-/-IL-7-/- mice. Mice were either left untreated or received IL-2/αIL-2 (1 μg/5 μg) complexes at day 1, 2 and 3 after transfer.
addition to lymphopenic contexts, complementary IL-7 signaling could be involved in Treg maintenance in non-lymphoid tissues were IL-2 producing cells are present in limited numbers. In accordance, Gratz et al. have recently reported that skin infiltrating Treg are mainly dependent on IL-7 for their maintenance [39], as suggested by high CD127 expression at their surface [34], [39].

Demonstration of IL-7 dependent modulation of IL-2 signaling also provides a rationale for the association between T cell lymphopenia and Treg enrichment [48]–[49]. Despite not being absolutely necessary for Treg expansion in lymphopenic setting [9], IL-2 and lymphopenia have been shown to synergize in the induction of Treg expansion after transfer into empty hosts [10]. We studied the specific impact of IL-7 on purified Treg by transfer into empty hosts competent or not for IL-7 when co-injected with IL-2 thus providing the critical factor for Treg survival and expansion. Even in this context highly favorable for Treg expansion, we demonstrated in vivo that IL-7 availability influences the expansion of the Treg pool during IL-2 induced Treg proliferation. This observation provides a scientific background to protocols currently under clinical evaluation employing very low doses of IL-2 to induce selective expansion of Treg cells during immune-recovery from lymphopenia after hematopoietic stem cell transplantation [50]–[51].

IL-7 plays a critical role in conventional CD4+FOXP3- T cells proliferation and expansion upon transfer into lymphopenic hosts [52] and, similarly to what we reported for the Treg compartment, IL-7 modulates CD25 expression on activated conventional T cells [44]–[47]. We can therefore speculate that IL-7 effect on conventional T cells expansion in lymphopenic contexts could, at least partially, be mediated by its ability to sustain CD25 expression thus allowing to better perceive and transduce IL-2 signaling. This hypothesis merits investigation in future studies aiming to better understand the effects of IL-7 on conventional T cells homeostasis.

In addition to the impact of IL-7 on Treg homeostasis, IL-7 modulation CD25 expression at Treg surface could also affect Treg cells suppressive capacity. High CD25 expression allows Treg cells to efficiently bind and compete for IL-2 produced by conventional T cells during the early phases of immune responses [53] thus suppressing activated conventional T cells proliferation [12], [54] and survival [13]. By increasing CD25 expression at Treg surface, IL-7 could theoretically increase the competitive potential of Treg for IL-2 and therefore their suppressive activity. Intrinsic higher suppressive capacity of CD25+ compared to CD25- Treg fraction has not been previously established and remain uneasy to address: standard in vitro suppressive assay does not allow to conclude on intrinsic suppressive capacity because integrating survival and proliferation in addition to
the strict intrinsic suppression capacity of each subsets. Similarly, in vitro suppressive assay in the presence or absence of IL-7 does not allow to directly ascertain the impact of IL-7 suppression because interfering both with conventional and Treg cells.

In summary, we established in the present report a role for IL-7 signaling in regulation of CD25 surface expression on Treg cells thus demonstrating an interplay between IL-2 and IL-7. In addition to provide IL-2 independent survival signals to Treg (as previously reported), IL-7 also constitutes an important cofactor for IL-2 induced expansion of Treg. IL-7 optimizes IL-2 consumption by Treg which may reveal extremely powerful to preserve Treg homeostasis.

Supporting Information

S1 Figure. IL-7 signaling does not modulate CD122 expression on Treg cells in vitro. (A) Total CD4+ cells isolated from FOXP3GFP mice were incubated overnight untreated (NT) or treated overnight with IL-2 (2 ng/ml) or IL-7 (10 ng/ml). (B) Representative FACS profiles of CD122 expression. CD122 expression on fresh (open histogram) and incubated (filled histogram) Foxp3/GFP+ cells and isotype control staining are shown. (C) MFI of CD122 expression on CD4+TCRβ+FOXP3+ cells after culture are shown. Mean ± SEM from three independent experiments are shown.
doi:10.1371/journal.pone.0113314.s001 (TIF)

S2 Figure. STAT5 phosphorylation in FOXP3+ Treg and FOXP3- conventional CD4 T cells upon IL-2 exposure. (A) Representative dot plot gated on TCRβ+ lymphocytes showing gating for CD4+ FOXP3- and FOXP3+ cells. (B) FACS profiles of phospho-STAT5 in FOXP3- (left panel) and FOXP3+ (right panel) cells either left untreated (unfilled histograms) or exposed to high doses IL-2 (10 ng/ml) (grey filled histograms). Isotype controls are indicated.
doi:10.1371/journal.pone.0113314.s002 (TIF)

Acknowledgments

We thank Dr Sophie Ezine and Dr Benedict Seddon for providing mice. We thank Pr. Marc Tardieu and Pr Jean-François Delfraissy for their support.

Author Contributions

Conceived and designed the experiments: FS CB. Performed the experiments: FS NG SB. Analyzed the data: FS NG CB. Wrote the paper: FS CB.

References

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151–1164.
2. Baecher-Allan C, Brown J, Freeman GJ, Hafler D (2001) CD4+CD25high Regulatory Cells in Human Peripheral Blood. J Immunol 167: 1245–1253.

3. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142–1151.

4. Soper DM, Kasprowicz DJ, Ziegler SF (2007) IL-2Rbeta links IL-2R signaling with Foxp3 expression. Eur J Immunol 37: 1817–1826.

5. Burchill M, Yang J, Vogtenhuber C, Blazar BR, Farrar M (2006) IL-2 Receptor-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells. J Immunol 178: 280–290.

6. Bayer L, Yu a., Malek TR (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142–1151.

7. Soper DM, Kasprowicz DJ, Ziegler SF (2007) IL-2Rbeta links IL-2R signaling with Foxp3 expression. Eur J Immunol 37: 1817–1826.

8. Burchill M, Yang J, Vogtenhuber C, Blazar BR, Farrar M (2006) IL-2 Receptor-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells. J Immunol 178: 280–290.

9. Almeida RM, Legrand N, Papiernik M, Freitas AA (2002) Homeostasis of Peripheral CD4+ T Cells: IL-2R and IL-2 Shape a Population of Regulatory Cells That Controls CD4+ T Cell Numbers. J Immunol 169: 4850–4860.

10. Bayer AL, Yu A, Adeegbe D, Malek TR (2005) Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201: 769–777.

11. Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723–735.

12. Zhang H, Chua KS, Guimond M, Kapoor V, Brown M V, et al. (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+)/CD25(-) regulatory T cells. Nat Med 11: 1238–1243.

13. Amado IF, Berges J, Luther RJ, Mailhe` M-P, Garcia S, et al. (2013) IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 210: 2707–2720.

14. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.

15. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8: 1353–1362.

16. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Pénit C (1998) Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 10: 371–378.

17. Amado IF, Berges J, Luther RJ, Mailhe` M-P, Garcia S, et al. (2013) IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 210: 2707–2720.

18. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.

19. Hor` S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061.

20. Zheng Y, Josefowicz SZ, Kas A, Chu T-T, Gavin M, et al. (2007) Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936–940.

21. Hill J, Feuerer M, Tash K, Haxhinasto S, Perez J, et al. (2007) Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27: 786–800.

22. Camperio C, Caristi S, Fanelli G, Soligo M, Del Porto P, et al. (2012) Forkhead transcription factor FOXP3 upregulates CD25 expression through cooperation with RelANF-xB. PLoS One 7: e48303.

23. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375–387.

24. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, et al. (2007) Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446: 685–689.

25. Kim HP, Kelly J, Leonard WJ (2001) The basis for IL-2-induced IL-2 receptor alpha chain gene regulation: importance of two widely separated IL-2 response elements. Immunity 15: 159–172.
25. Lin J-X, Li P, Liu D, Jin HT, He J, et al. (2012) Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 36: 586–599.

26. Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S (2006) CD4+CD25+Foxp3+ T Cells and CD4+CD25-Foxp3+ T Cells in Aged Mice. J Immunol 176: 6586–6593.

27. Raynor J, Sholl A, Plas DR, Bouillet P, Chougnet C, et al. (2013) IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels. Front Immunol 4: 161.

28. Pandiyan P, Lenardo MJ (2008) The control of CD4+CD25+Foxp3+ regulatory T cell survival. Biol Direct 3: 6.

29. Peffault de Latour R, Dujardin HC, Mishellany F, Burlen-Defranoux O, Zuber J, et al. (2006) Ontogeny, function, and peripheral homeostasis of regulatory T cells in the absence of interleukin-7. Blood 108: 2300–2306.

30. Mazzucchelli R, Hixon JA, Spolski R, Chen X, Li WQ, et al. (2008) Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood 112: 3283–3292.

31. Cozzo C, Larkin J, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25-Foxp3+ regulatory T cells. J Immunol 171: 5678–5682.

32. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, et al. (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203: 1693–1700.

33. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203: 1701–1711.

34. Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, et al. (2010) Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol 40: 2528–2538.

35. Juffroy O, Bugault F, Lambotte O, Landires I, Viard JP, et al. (2010) Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. J Virol 84: 96–108.

36. Dupont G, Demaret J, Venet F, Malergue F, Malcus C, et al. (2014) Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3(-) cells versus regulatory T cells: A whole blood perspective. Cytokine 69: 146–149.

37. Simonetta F, Gestermann N, Martinet KZ, Boniotto M, Tissières P, et al. (2012) Interleukin-7 influences FOXP3+CD4+ regulatory T cells peripheral homeostasis. PLoS One 7: e36596.

38. Kim GY, Ligons DL, Hong C, Luckey M, Keller HR, et al. (2012) An in vivo IL-7 requirement for peripheral FoxP3+ regulatory T cell homeostasis. J Immunol 188: 5859–5866.

39. Gratz IK, Truong H-A, Yang SH-Y, Maurano MM, Lee K, et al. (2013) Cutting Edge: memory regulatory T cells require IL-7 and not IL-2 for their maintenance in peripheral tissues. J Immunol 190: 4483–4487.

40. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924–7.

41. Park J-H, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, et al. (2004) Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 21: 289–302.

42. Guimond M, Veenstra RG, Grindler DJ, Zhang H, Cui Y, et al. (2009) Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 10: 149–157.

43. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, et al. (2001) A potential role for interleukin-7 in T-cell homeostasis. Blood 97: 2983–2990.

44. Morrissey PJ, Goodwin RG, Nordan RP, Anderson D, Grabstein KH, et al. (1989) Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med 169: 707–16.

45. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH (1990) Regulation of human T cell proliferation by IL-7. J Immunol 144: 938–41.

46. Grabstein KH, Namen AE, Reed SG, Widmer MB, Voice F (1990) Regulation of T cell proliferation by IL-7. J Immunol 144: 3015–20.
47. Costello R, Brailly H, Mallet F, Mawas C, Olive D (1993) Interleukin-7 is a potent co-stimulus of the adhesion pathway involving CD2 and CD28 molecules. Immunology 80: 451–457.

48. Bosco N, Agenes F, Rolink G, Ceredig R (2006) Peripheral T Cell Lymphopenia and Concomitant Enrichment in Naturally Arising Regulatory T Cells: The Case of the Pre-T Gene-Deleted Mouse. J Immunol 177: 5014–5023.

49. Lages CS, Suffia I, Velilla P, Huang B, Warshaw G, et al. (2008) Functional Regulatory T Cells Accumulate in Aged Hosts and Promote Chronic Infectious Disease Reactivation. J Immunol 181: 1835–1848.

50. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, et al. (2013) Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-vs-host disease. Sci Transl Med 5: 179ra43.

51. Kennedy-Nasser A, Ku S, Castillo-Caro P, Hazrat Y, Wu M-F, et al. (2014) Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 20: 2215–2225.

52. Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, et al. (2001) IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A. 98:8732–8737.

53. O’Gorman WE, Dooms H, Thorne SH, Kuswanto WF, Simonds EF, et al. (2009) The initial phase of an immune response functions to activate regulatory T cells. J Immunol 183: 332–339.

54. Barthlott T, Moncrieffe H, Veldhoen M, Atkins CJ, Christensen J, et al. (2005) CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol 17: 279–288.